Skip to main content

Translational Research Institute

Translational Research Institute

Clinical Trials

Showing 28-36 out of 37 results.
NCT06131372

NN9388-7700: Efficacy and safety of co-administered cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (cagrisema s.c. 2.4 mg/2.4 mg) once-weekly compared to semaglutide, cagrilinitide and placebo in people with chronic kidney disease and type 2 diabetes.

Icon for trial | NN9388-7700: Efficacy and safety of co-administered cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (cagrisema s.c. 2.4 mg/2.4 mg) once-weekly compared to semaglutide, cagrilinitide and placebo in people with chronic kidney disease an

Study Purpose: The purpose of this study is to see whether CagriSema can lower kidney damage. This will be compared to the effects of semaglutide, cagrilintide and placebo. Study Duration: Approximately 35 weeks Study Commitmen ...

NCT04805970

RECODE: Researching Covid Outcomes in Diabetes

Icon for trial | RECODE: Researching Covid Outcomes in Diabetes

We invite you to take part in a research study because you have previously had a confirmed diagnosis for COVID-19 (the new coronavirus) disease. You have recovered, or are recovering from this disease, with no fever or cough wi ...